Methods for inducing pupil dilation
View Patent ↗The present invention provides methods for inducing or enhancing rapid and significant dilation of a subject's pupils. In certain embodiments, the method comprises upregulating the alpha-1 receptors in the eye of the subject, thereby increasing sensitivity to alpha-1 agonists. In other embodiments, such upregulation is achieved through administration of at least one compound selected from the group consisting of alpha-2 selective agonists and beta adrenoreceptor antagonists for a period of time prior to the intended time of dilation. After inducing the upregulation of alpha-1 receptors through the administration of at least one compound selected from the group consisting of alpha-2 selective agonists and beta adrenoreceptor antagonists, alpha-1 agonists can be administered to induce or enhance rapid and strong pupil dilation.
1. A method for enhancing dilation of a pupil of a subject, the method comprising administering to the subject,
a first composition comprising at least one alpha-2 selective agonist, or a salt or solvate thereof; and
a second composition comprising at least one alpha-1 agonist or a salt or solvate thereof, wherein administering comprises administering at least one dose of the first composition to a subject's eye and subsequently administering at least one hour up to 30 days later at least one dose of the second composition to the subject's eye, wherein the second composition induces pupil dilation, and the second composition comprises at least one alpha-1 agonist selected from the group consisting of cirazoline, epinephrine, etilefrine, metaraminol, methoxamine, midodrine, naphazoline, norepinephrine, oxymetazoline, phenylephrine, pseudoephedrine, tetrahydrozoline, and synephrine, or a salt or solvate thereof, and wherein the first composition has an alpha-2:alpha-1 affinity ratio of greater than 200.
2. The method of claim 1 , wherein the first composition comprises at least one alpha-2 selective agonist-selected from the group consisting of: amitraz, cannabigerol, brimonidine, detomidine, dexmedetomidine, fadolmidine, guanabenz, guanfacine, lofexidine, marsanidine, 7-Me-marsanidine, medetomidine, methamphetamine, mivazerol, 4-NEMD, rilmenidine, romifidine, talipexole, tiamenidine, tizanidine, tolonidine, vortioxetine, and xylazine, or a salt or solvate thereof.
3. The method of claim 1 , wherein the second composition comprises at least one of epinephrine and phenylephrine, or a salt or solvate thereof.
4. The method of claim 1 , wherein the first composition comprises at least one of brimonidine and dexmedetomidine, and wherein the second composition comprises at least one of phenylephrine and epinephrine.
5. The method of claim 1 , wherein the first composition comprises a concentration from about 0.001% to about 50% (v/v) per dose; and wherein the second composition comprises a concentration from about 0.001% to about 50% (v/v) per dose.
6. The method of claim 1 , wherein the second composition is administered to the subject from about 1 day to about 10 days after administration of the first composition.
7. The method of claim 1 , wherein the first composition is administered to the subject two or more times before the second composition is administered.
8. The method of claim 1 , wherein the first composition is administered at least once per day for about 1 day to about 10 days.
9. The method of claim 1 , wherein the first composition is a pharmaceutical composition formulated for topical administration.
10. The method of claim 1 , wherein the first composition is a pharmaceutical composition formulated as an ophthalmic drop, ophthalmic ointment, ophthalmic gel, ophthalmic spray or ophthalmic lotion.
11. The method of claim 1 , wherein the second composition is a pharmaceutical composition formulated for topical administration.
12. The method of claim 1 , wherein the second composition is a pharmaceutical composition formulated as an ophthalmic drop, ophthalmic ointment, ophthalmic gel, ophthalmic spray, ophthalmic lotion, or ophthalmic intracameral injection.
13. The method of claim 1 , wherein the first composition and the second composition are administered to the subject by at least one of the following routes: topically; through intracameral injection; or, directly applied to at least one portion of the eye of the subject.
14. A kit comprising at least one dose of a first composition comprising at least one alpha-2 selective agonist; and at least one dose of a second composition comprising at least one alpha-1 agonist wherein and the second composition comprises at least one alpha-1 agonist selected from the group consisting of cirazoline, epinephrine, etilefrine, metaraminol, methoxamine, midodrine, naphazoline, norepinephrine, oxymetazoline, phenylephrine, pseudoephedrine, tetrahydrozoline, and synephrine, or a salt or solvate thereof, and wherein the first composition has an alpha-2:alpha-1 affinity ratio of greater than 200; and at least one container.
15. The kit of claim 14 , wherein the first composition comprises at least one alpha-2 selective agonist-selected from the group consisting of, amitraz, cannabigerol, brimonidine, detomidine, dexmedetomidine, fadolmidine, guanabenz, guanfacine, lofexidine, marsanidine, 7-Me-marsanidine, medetomidine, methamphetamine, mivazerol, 4-NEMD, rilmenidine, romifidine, talipexole, tiamenidine, tizanidine, tolonidine, vortioxetine, and xylazine, or a salt or solvate thereof.
16. The kit of claim 14 , wherein the kit comprises at least two doses of the first composition and at least one dose of the second composition.
17. The kit of claim 14 , further comprising materials containing instructions for using the at least one dose of a first composition comprising at least one alpha-2 selective agonist and the at least one dose of a second composition comprising at least one alpha-1 agonist.
18. The kit of claim 14 , wherein the at least one alpha-2 selective agonist comprises at least one of brimonidine and dexmedetomidine, and
wherein the at least one alpha-1 agonist comprises at least one of phenylephrine and epinephrine.
19. The method of claim 13 , wherein applying directly to at least one portion of the eye of the subject comprises applying directly to at least one of the cornea, iris, sclera, conjunctiva, or anterior chamber of the subject's eye.
20. The method of claim 1 , wherein the first composition has an affinity ratio of alpha-2:alpha-1 of about 800 or greater.
21. The method of claim 1 , wherein the first composition has an affinity ratio of alpha-2:alpha-1 of about 976 or greater.
22. The method of claim 1 , wherein administering the at least one dose of the first composition to the subject's eye comprises administering the at least one dose of the first composition to the subject's eye to induce at least one of an increase in the amount or sensitivity of alpha 1 receptors on iris dilator muscles of the subject's eye.
23. The method of claim 1 , wherein the first composition comprises dexmedetomidine.
24. The method of claim 1 , wherein the first composition comprises a concentration of about 0.01% to about 0.5% (v/v) per dose.
25. The method of claim 1 , wherein the first composition comprises an ophthalmic drop.
26. The method of claim 1 , further comprising administering to the subject the first composition as an ophthalmic drop twice to four times per day for 1 day up to 10 days at a dose concentration of about 0.01% to about 0.5% (v/v) dexmedetomidine; and administering the second composition about 1 day up to about 10 days after administering the first composition.